Triaging antibody sequences from high-throughput next-generation sequence data for development of effective therapeutics
Lead Research Organisation:
University College London
Department Name: Cell and Developmental Biology
Abstract
A major class of drugs is now antibody-based. Recent approaches to antibody drug
development use NGS sequencing of antibody libraries from transgenic mice, human serum
or phage display with companies such as Kymab regularly generating 10^6 sequences per
week. AM's abYsis software is used by a number of companies to analyze antibodies, but is
not designed for this type of high throughput. The project will develop novel software to allow
large libraries to be analyzed and triaged (looking for unusual features and developability
liabilities) before loading into abYsis for further analysis and interface with BRepertoire from
FF's lab.
development use NGS sequencing of antibody libraries from transgenic mice, human serum
or phage display with companies such as Kymab regularly generating 10^6 sequences per
week. AM's abYsis software is used by a number of companies to analyze antibodies, but is
not designed for this type of high throughput. The project will develop novel software to allow
large libraries to be analyzed and triaged (looking for unusual features and developability
liabilities) before loading into abYsis for further analysis and interface with BRepertoire from
FF's lab.
Organisations
People |
ORCID iD |
| Andrew Martin (Primary Supervisor) | |
| James Sweet-Jones (Student) |
Studentship Projects
| Project Reference | Relationship | Related To | Start | End | Student Name |
|---|---|---|---|---|---|
| BB/T008709/1 | 01/10/2020 | 30/09/2028 | |||
| 2397806 | Studentship | BB/T008709/1 | 01/10/2020 | 30/09/2024 | James Sweet-Jones |